ARC
AGIO icon

Absolute Return Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Absolute Return Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,724
Closed -$125K – 616
2014
Q2 		$125K Sell
2,724
-24,491
-90% -$998K ﹤0.01% 1095
2014
Q1 		$1.06M Buy
+27,215
New +$911K 0.02% 617

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Absolute Return Capital's AGIO Position: Q3 2014 in Review

Absolute Return Capital sold out of Agios Pharmaceuticals (AGIO) in Q3 2014, closing a stake of 2,724 shares — an estimated $125K sold.

Absolute Return Capital first reported a position in AGIO in Q1 2014 and held it in 2 quarters. The position peaked at $1.06M in Q1 2014. 120 funds tracked by Wall St. Rank hold AGIO as of Q3 2014.

  • Absolute Return Capital reported no remaining Agios Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Absolute Return Capital sold 2,724 Agios Pharmaceuticals shares in Q3 2014, an estimated $125K.
  • Absolute Return Capital first reported a position in Agios Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Absolute Return Capital's Agios Pharmaceuticals position peaked at $1.06M in Q1 2014.
  • 120 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2014.

Based on Absolute Return Capital's 13F filing for Q3 2014, filed 14 Nov 2014.